Roche Commits Up To $1bn For Blueprint's Immunokinase Inhibitors
This article was originally published in Scrip
Executive Summary
When Blueprint Medicines Corp. sought a partner to help advance its kinase inhibitors with the potential to boost immune responses to cancer, the company came up with a short list of ideal big pharma collaborators and Roche rose to the top.
You may also be interested in...
Oncology Focused Investment Comes Into Its Own
UBS closed its $471m Oncology Impact Fund, a specialist investment vehicle for early stage oncology, in April this year. But it was by no means the first commercial investment vehicle to focus solely on oncology. Nextech Invest raised its fourth oncology fund in July this year.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.